Background: Neuronal intranuclear inclusion disease (NIID) is a progressive neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in neuronal and somatic cells. Because of the variety of clinical manifestations, antemortem diagnosis of NIID is difficult.
Neuronal intranuclear inclusion disease (NIID), also known as neuronal intranuclear hyaline inclusion disease, is a progressive neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in neuronal and visceral organ cells. [1] [2] [3] [4] Clinical manifestations of NIID are highly variable and can include pyramidal and extrapyramidal symptoms, cerebellar ataxia, dementia, convulsion, neuropathy, and autonomic dysfunction. [1] [2] [3] [4] [5] [6] Both sporadic and familial cases have been reported, and the onset of disease varies from infantile stages to late middle age. [1] [2] [3] [4] [5] [6] The antemortem diagnosis of NIID is difficult, and most of the reported cases of NIID are diagnosed by postmortem histopathologic examination. Some reports have described antemortem diagnosis of NIID by rectal biopsy 5, 6 and sural nerve biopsy. 2 However, rectal biopsy has a risk of perforation, 7 and sural nerve biopsy is applicable only in patients with sensory disturbance. 2 To avoid the difficulty of antemortem diagnosis of NIID by rectal or sural nerve biopsy, we investigated skin biopsy samples from patients with familial NIID and compared the findings with those of samples from normal control subjects and from patients with other neurodegenerative diseases. Our results suggest that skin biopsy is a useful and safe tool for the antemortem diagnosis of NIID.
METHODS Subjects. Skin tissue samples were collected from autopsy samples, and skin biopsy samples were collected from patients at Nagoya University Hospital and from normal volunteers. Overall, skin biopsy samples from 7 patients with familial NIID from 2 pedigrees, as we reported previously, 2 were analyzed. Patients with sporadic NIID were not included. For other neurodegenerative diseases, 3 biopsy samples from patients with Charcot-Marie-Tooth (CMT) disease with PMP22 duplication, 2 autopsy samples and one biopsy sample from patients with familial amyloid polyneuropathy (FAP), one biopsy sample from a patient with genetically diagnosed Huntington disease (HD), 3 biopsy samples from patients with spinocerebellar ataxia 3 (SCA3), 3 biopsy samples from patients with dentatorubral pallidoluysian atrophy (DRPLA), 2 autopsy samples and one biopsy sample from patients with spinal and bulbar muscular atrophy (SBMA), 3 autopsy samples from patients with sporadic amyotrophic lateral sclerosis (ALS), 2 autopsy samples and one biopsy sample from patients with Parkinson disease (PD), one autopsy sample and 2 biopsy samples from patients with multiple system atrophy (MSA), 2 autopsy samples and one biopsy sample from patients with progressive supranuclear palsy (PSP), and 8 samples from normal volunteers were analyzed. All the patients with CMT, FAP, SCA3, DRPLA, and SBMA were assessed genetically.
Standard protocol approvals, registrations, and patient consent.
The study was performed with approved protocols and informed consent in accordance with the institutional review board of Nagoya University School of Medicine. Written informed consent was obtained from all patients and normal volunteers.
Skin biopsy, immunohistochemistry, and electron microscopic study. After local anesthesia, a 3-mm-diameter punch biopsy specimen was obtained at 10 cm above the lateral malleolus. All samples were fixed in 10% formalin. Sections of all samples (4 m) were stained by hematoxylin & eosin (H&E), and immunohistochemical analysis was performed using a Ventana DISCOVERY system (Ventana Medical Systems, Tucson, AZ). Sections were incubated with anti-ubiquitin antibody (Z0458; DAKO, Glostrup, Denmark) and anti-SUMO1 antibody (sc-5308; Santa Cruz Biotechnology, Santa Cruz, CA) using the Ventana DAB Map kit. For immunofluorescence staining, sections were blocked with 4% goat serum and incubated in anti-ubiquitin antibody (P4D1; Santa Cruz Biotechnology). Bound anti-ubiquitin antibody was visualized using antimouse goat immunoglobulin G coupled with Alexa Fluor 488 (Molecular Probes, Eugene, OR). Nuclei were stained with 1.5 g/mL 4Ј,6-diamidino-2-phenyindole di-lactate (DAPI). Samples for electron microscopy were fixed in glutaraldehyde in cacodylate buffer and embedded in epoxy resin. 8
RESULTS
We performed more than 30 skin biopsies with no adverse reaction or accident. H&Estained sections from patients with NIID demonstrated eosinophilic intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells in the dermis (figure 1, A-C). The nuclei of these cells were strongly stained basophilic, which made it difficult to observe inclusions in such small, dark-stained nuclei (figure 1, A-C). In anti-ubiquitin-stained sections using the DAB technique (figure 1, D-F), intranuclear inclusions were identified easily in all 7 NIID samples. However, erythrocytes and some secreted materials from the sweat glands were strongly stained with the anti-ubiquitin antibody, which made it difficult to distinguish these materials from intranuclear inclusions.
By examination using electron microscopy, intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells showed common features (figure 1, G-L). These inclusions were composed of filamentous material and showed no limiting membrane. The nuclei of adipocytes were observed as entirely electron dense, but we were able to identify inclusions in the nuclei of adipocytes (figure 1, G and J). The nuclei of fibroblasts were less electron dense than those of adipocytes, and inclusions were recognized easily as electron-dense spherical bodies and filaments arranged in turbinate fashion (figure 1, H and K). In the sweat gland cells, intranuclear inclusions were observed as electron light material in the nucleus (figure 1, I and L).
We also examined anti-SUMO1 antibody immunoreactivity. SUMO1 is a small ubiquitin-like modifier protein that covalently conjugates to various intracellular target proteins to alter their cellular distribution, function, and metabolism. Neuronal intranuclear inclusions of patients with NIID are immunoreactive for SUMO1. 9 Intranuclear inclusions in the dermal cells showed anti-SUMO1 immunoreactivity (figure 1, M-O), similar to results previously reported for NIID neuronal cells. 1, 9 These features of inclusions are identical to those of neuronal inclusions in patients with NIID (figure 1, P-T). 2
Frequency of intranuclear inclusions.
We investigated the frequency of intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells using antiubiquitin antibody and DAPI for the purpose of distinguishing intranuclear inclusions from other ubiquitin-positive materials. Intranuclear inclusions were recognized readily as ubiquitin-positive inclusions within DAPI-positive nuclei under merge view ( figure 2A) . The frequency of intranuclear inclusionpositive adipocytes in NIID skin samples was approximately 10%, which represented the highest frequency among the 3 cell types (table) . 
DISCUSSION
In H&E-stained sections from patients with familial NIID, we observed intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells, but difficulty in observing the inclusions was encountered because of the size and density of the nuclei. Immunohistochemical analysis using antiubiquitin antibody with a DAB-based technique re-vealed intranuclear inclusions more distinctly than H&E staining. These results suggest that double fluorescence staining with anti-ubiquitin antibody and DAPI is a more reliable method to detect intranuclear inclusions in skin samples from patients with NIID, and we recommend this method for the diagnosis of NIID.
Intranuclear inclusions detected in adipocytes, fibroblasts, and sweat gland cells in skin samples were visible in H&E-stained sections, were positive for anti-ubiquitin antibody and anti-SUMO1 antibody, and showed filamentous materials and no limiting membrane. These features of inclusions are identical to those reported for NIID inclusions in neuronal cells ( figure 1 ). [1] [2] [3] [4] 9 We suggest that the intranuclear inclusions in dermal cells have a pathologic background similar to that of neuronal cells and are useful for NIID diagnosis. Furthermore, because no intranuclear inclusions were observed in dermal cells from normal control samples and other neurodegenerative disease skin samples, skin biopsy is a powerful tool for the differential diagnosis of NIID from other neurologic diseases. The examination of a few slides of doubleimmunostained skin samples may be sufficient for the diagnosis of NIID because the frequency of intranuclear inclusions in adipocytes was approximately 10%. Skin biopsy is an accepted and established technique. 10 It requires only local anesthesia and is safer and easier and presents less stress to patients than rectal biopsy or sural nerve biopsy. Taken together, our results suggest that skin biopsy is an acceptable and less invasive tool for the antemortem diagnosis of NIID. 
